In the BioHarmony Drug Report Database

"Preview" Icon

Tigecycline

Tigecycline, Tygacil (tigecycline) is a small molecule pharmaceutical. Tigecycline was first approved as Tigecycline on 2005-06-15. It is used to treat bacteremia, bacterial infections, bacterial pneumonia, bacterial skin diseases, and bacteroides infections amongst others in the USA. It has been approved in Europe to treat bacterial infections, bacterial skin diseases, infectious skin diseases, intraabdominal infections, and soft tissue infections. Tygacil’s patents are valid until 2033-04-07 (FDA).

 

Trade Name

 

Tygacil
 

Common Name

 

tigecycline
 

ChEMBL ID

 

CHEMBL376140
 

Indication

 

bacteremia, bacterial infections, bacterial pneumonia, bacterial skin diseases, bacteroides infections, clostridium infections, escherichia coli infections, haemophilus infections, infectious skin diseases, intraabdominal infections, klebsiella infections, legionellosis, soft tissue infections, staphylococcal infections, streptococcal infections
 

Drug Class

 

Antibiotics (tetracycline derivatives)

Image (chem structure or protein)

Tigecycline structure rendering